Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Lunan Pharmaceutical Group Corporation has 2 pending office actions distributed across the Biotechnology & Pharmaceuticals technology area. These matters are spread between 2 distinct examiners and 2 distinct art units, showing a diversified prosecution landscape for the current workload. PECKHAM, RICHARD GRANT is identified as the busiest examiner, currently managing 1 busiest examiner pending action. This represents 1 of the 2 total pending office actions for the company.
The use of 2 separate art units suggests that the pending applications cover different specialized sub-sectors within the broader pharmaceutical field. Because the 2 pending office actions are split among 2 distinct examiners, the prosecution team must navigate different individual preferences and examination styles. PECKHAM, RICHARD GRANT handles 1 busiest examiner pending case, leaving the other action to a second examiner. This distribution requires a flexible approach to address the specific requirements of each of the 2 distinct art units involved in the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17640785 | MAGL INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | COPPINS, JANET L | 18d overdue |
| 17779165 | OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17779165 | OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | PECKHAM, RICHARD GRANT | 1627 | §103 | Final Rejection | — | Pending | May 24, 2022 |
| 17640785 | MAGL INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | COPPINS, JANET L | 1628 | §112 | Final Rejection | 18d overdue | Pending | Mar 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial